applicability and precautions of use of liver injury biomarker fibrotest. a reappraisal at 7 years of age适用性和预防肝损伤生物标志物fibrotest的使用。.pdfVIP

下载本文档

1
0
约7.34万字
约 11页
2017-09-11 发布于上海
举报
版权申诉

applicability and precautions of use of liver injury biomarker fibrotest. a reappraisal at 7 years of age适用性和预防肝损伤生物标志物fibrotest的使用。.pdf

1、本文档共11页，可阅读全部内容。
2、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。
3、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
5、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
6、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
7、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
8、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

applicability and precautions of use of liver injury biomarker fibrotest. a reappraisal at 7 years of age适用性和预防肝损伤生物标志物fibrotest的使用。

Poynard et al. BMC Gastroenterology 2011, 11:39 /1471-230X/11/39 RESEARCH ARTICLE Open Access Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age 1* 2 2 2 2 1 Thierry Poynard , Mona Munteanu , Olivier Deckmyn , Yen Ngo , Fabienne Drane , Djamila Messous , 2 1 1 1 Jean Marie Castille , Chantal Housset , Vlad Ratziu and Françoise Imbert-Bismut Abstract Background: FibroTest (FT) is a validated biomarker of fibrosis. To assess the applicability rate and to reduce the risk of false positives/negatives (RFPN), security algorithms were developed. The aims were to estimate the prevalence of RFPN and of proven failures, and to identify factors associated with their occurrences. Methods: Four populations were studied: 954 blood donors (P1), 7,494 healthy volunteers (P2), 345,695 consecutive worldwide sera (P3), including 24,872 sera analyzed in a tertiary care centre (GHPS) (P4). Analytical procedures of laboratories with RFPN 5% and charts of P4 patients in with RFPN were reviewed. Results: The prevalence of RFPN was 0.52% (5/954; 95%CI 0.17-1.22) in P1, 0.51% (38/7494; 0.36-0.70) in P2, and 0.97% (3349/345695; 0.94-1.00) in P3. Three a priori high-risk populations were confirmed: 1.97% in P4, 1.77% in HIV centre and 2.61% in Sub-Saharan origin subjects. RFPN was mostly associated with low haptoglobin (0.46%), and high apolipoproteinA1 (0.21%). A traceability study of a P3 laboratory with RFPFN 5% permitted to correct analytical procedures. Conclusion: The mean applicability rate of Fibrotest was 99.03%. Independent factors associated with the high